Finally, the correction of the BMPR2 mutation in FPAH patient derived iPSC-endothelial cells restored signaling and EC function, which suggested that identified protective modifiers for FPAH that could help to inform the development of future treatment strategies [120]. This evidence concerns the gene BMPR2 and heritable pulmonary arterial hypertension.